A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease

Treatment of chronic obstructive pulmonary disease (COPD) with inhaled and oral corticosteroids is common, although their exact role is unclear. Previous studies suggest these drugs may reduce decline in lung function in this group of patients. We report a study investigating the effect of inhaled b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental allergy 1999-06, Vol.29 (s2), p.125-128
Hauptverfasser: Weir, D. C., Bale, G. A., Bright, P., Sherwood Burge, P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 128
container_issue s2
container_start_page 125
container_title Clinical and experimental allergy
container_volume 29
creator Weir, D. C.
Bale, G. A.
Bright, P.
Sherwood Burge, P.
description Treatment of chronic obstructive pulmonary disease (COPD) with inhaled and oral corticosteroids is common, although their exact role is unclear. Previous studies suggest these drugs may reduce decline in lung function in this group of patients. We report a study investigating the effect of inhaled beclomethasone diproprionate (BDP) on lung function and symptoms in a group of patients with COPD. Treatment was given for 2 years, and the decline in FEV1 in individual patients calculated over this period. Ninety‐eight patients were randomized for the study, 59 completing 2 years of treatment. Patients withdrawn had more severe airflow obstruction. Decline in FEV1, measured both prior to and after bronchodilator, was less in patients receiving inhaled BDP, although the differences failed to reach statistical significance except in a subgroup of patients with more severe airflow obstruction. Exacerbation rates were also reduced by inhaled BDP, but again the differences failed to reach conventional levels of statistical significance. The results of this study are consistent with previous published work, but further insight into the long‐term role of corticosteroids in COPD await the publication of large studies which have recently been completed. Although the changes seen in this study and others are numerically small, the rate of decline in FEV1 returned to normal levels expected from age‐related decline, and hence such treatment combined with other strategies may well have a significant role in the long‐term treatment of this condition.
doi_str_mv 10.1046/j.1365-2222.1999.00021.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69917795</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>43348791</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3601-b65e50d9bdfd774cbcffdc5875780d1032465b88efa80cec6fec845b49d73c043</originalsourceid><addsrcrecordid>eNqNkVGP1CAUhRujccfVv2CID761QltaiE-TcXc1WTUajb4RCrcpIy1doO7Mf_JHSp3NxvgkLzdwv3PCyckyRHBBcN282hekamheplMQznmBMS5JcXiQbe4XD7MN5rTOW8brs-xJCPsEVZSzx9lZMikJq-gm-7VF2i2dhbyzZtJotlJB53LlpuidtaBRiIs-ItejOACCvgcV15uZBrmuO1DWjRAHGdwESJvZu9m4SUZAvfOoREeQPiQezTIamGJAtyYOaEpMiMOYHhVSg3dTmq4L0S8qmp-A5sWOifHHZBpABniaPeqlDfDsbp5nXy8vvuze5tcfr97ttte5qhpM8q6hQLHmne5129aqU32vFWUtbRnWBFdl3dCOMeglwwpUkyKxmnY1122lcF2dZy9PvinKzQIhitEEBdbKCdwSRMM5aVtOE_jiH3DvFj-lv4lUC2vrqmYJYidIeReCh17M3owpliBYrHWKvVhbE2trq46LP3WKQ5I-v_NfuhH0X8JTfwl4fQJujYXjfxuL3cW2JEmdn9QmRDjcq6X_IZq2aqn49uFKNJfvv3-mn5h4U_0GvUnBrQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>199874348</pqid></control><display><type>article</type><title>A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Weir, D. C. ; Bale, G. A. ; Bright, P. ; Sherwood Burge, P.</creator><creatorcontrib>Weir, D. C. ; Bale, G. A. ; Bright, P. ; Sherwood Burge, P.</creatorcontrib><description>Treatment of chronic obstructive pulmonary disease (COPD) with inhaled and oral corticosteroids is common, although their exact role is unclear. Previous studies suggest these drugs may reduce decline in lung function in this group of patients. We report a study investigating the effect of inhaled beclomethasone diproprionate (BDP) on lung function and symptoms in a group of patients with COPD. Treatment was given for 2 years, and the decline in FEV1 in individual patients calculated over this period. Ninety‐eight patients were randomized for the study, 59 completing 2 years of treatment. Patients withdrawn had more severe airflow obstruction. Decline in FEV1, measured both prior to and after bronchodilator, was less in patients receiving inhaled BDP, although the differences failed to reach statistical significance except in a subgroup of patients with more severe airflow obstruction. Exacerbation rates were also reduced by inhaled BDP, but again the differences failed to reach conventional levels of statistical significance. The results of this study are consistent with previous published work, but further insight into the long‐term role of corticosteroids in COPD await the publication of large studies which have recently been completed. Although the changes seen in this study and others are numerically small, the rate of decline in FEV1 returned to normal levels expected from age‐related decline, and hence such treatment combined with other strategies may well have a significant role in the long‐term treatment of this condition.</description><identifier>ISSN: 0954-7894</identifier><identifier>EISSN: 1365-2222</identifier><identifier>DOI: 10.1046/j.1365-2222.1999.00021.x</identifier><identifier>PMID: 10421835</identifier><language>eng</language><publisher>Oxford BSL: Blackwell Science Ltd</publisher><subject>Administration, Inhalation ; Aged ; Beclomethasone - therapeutic use ; Bronchial Provocation Tests ; chronic obstructive pulmonary disease ; Disease Progression ; Double-Blind Method ; Female ; FEV1 decline ; Forced Expiratory Volume ; Glucocorticoids - therapeutic use ; Humans ; inhaled beclomethasone ; Lung - drug effects ; Lung - physiopathology ; Lung Diseases, Obstructive - drug therapy ; Lung Diseases, Obstructive - physiopathology ; Male ; Nebulizers and Vaporizers ; randomized control trial ; Treatment Outcome</subject><ispartof>Clinical and experimental allergy, 1999-06, Vol.29 (s2), p.125-128</ispartof><rights>Blackwell Science Ltd, Oxford</rights><rights>Copyright Blackwell Scientific Publications Ltd. Jun 1999</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3601-b65e50d9bdfd774cbcffdc5875780d1032465b88efa80cec6fec845b49d73c043</citedby><cites>FETCH-LOGICAL-c3601-b65e50d9bdfd774cbcffdc5875780d1032465b88efa80cec6fec845b49d73c043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2222.1999.00021.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2222.1999.00021.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10421835$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weir, D. C.</creatorcontrib><creatorcontrib>Bale, G. A.</creatorcontrib><creatorcontrib>Bright, P.</creatorcontrib><creatorcontrib>Sherwood Burge, P.</creatorcontrib><title>A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease</title><title>Clinical and experimental allergy</title><addtitle>Clinical &amp; Experimental Allergy</addtitle><description>Treatment of chronic obstructive pulmonary disease (COPD) with inhaled and oral corticosteroids is common, although their exact role is unclear. Previous studies suggest these drugs may reduce decline in lung function in this group of patients. We report a study investigating the effect of inhaled beclomethasone diproprionate (BDP) on lung function and symptoms in a group of patients with COPD. Treatment was given for 2 years, and the decline in FEV1 in individual patients calculated over this period. Ninety‐eight patients were randomized for the study, 59 completing 2 years of treatment. Patients withdrawn had more severe airflow obstruction. Decline in FEV1, measured both prior to and after bronchodilator, was less in patients receiving inhaled BDP, although the differences failed to reach statistical significance except in a subgroup of patients with more severe airflow obstruction. Exacerbation rates were also reduced by inhaled BDP, but again the differences failed to reach conventional levels of statistical significance. The results of this study are consistent with previous published work, but further insight into the long‐term role of corticosteroids in COPD await the publication of large studies which have recently been completed. Although the changes seen in this study and others are numerically small, the rate of decline in FEV1 returned to normal levels expected from age‐related decline, and hence such treatment combined with other strategies may well have a significant role in the long‐term treatment of this condition.</description><subject>Administration, Inhalation</subject><subject>Aged</subject><subject>Beclomethasone - therapeutic use</subject><subject>Bronchial Provocation Tests</subject><subject>chronic obstructive pulmonary disease</subject><subject>Disease Progression</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>FEV1 decline</subject><subject>Forced Expiratory Volume</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>inhaled beclomethasone</subject><subject>Lung - drug effects</subject><subject>Lung - physiopathology</subject><subject>Lung Diseases, Obstructive - drug therapy</subject><subject>Lung Diseases, Obstructive - physiopathology</subject><subject>Male</subject><subject>Nebulizers and Vaporizers</subject><subject>randomized control trial</subject><subject>Treatment Outcome</subject><issn>0954-7894</issn><issn>1365-2222</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkVGP1CAUhRujccfVv2CID761QltaiE-TcXc1WTUajb4RCrcpIy1doO7Mf_JHSp3NxvgkLzdwv3PCyckyRHBBcN282hekamheplMQznmBMS5JcXiQbe4XD7MN5rTOW8brs-xJCPsEVZSzx9lZMikJq-gm-7VF2i2dhbyzZtJotlJB53LlpuidtaBRiIs-ItejOACCvgcV15uZBrmuO1DWjRAHGdwESJvZu9m4SUZAvfOoREeQPiQezTIamGJAtyYOaEpMiMOYHhVSg3dTmq4L0S8qmp-A5sWOifHHZBpABniaPeqlDfDsbp5nXy8vvuze5tcfr97ttte5qhpM8q6hQLHmne5129aqU32vFWUtbRnWBFdl3dCOMeglwwpUkyKxmnY1122lcF2dZy9PvinKzQIhitEEBdbKCdwSRMM5aVtOE_jiH3DvFj-lv4lUC2vrqmYJYidIeReCh17M3owpliBYrHWKvVhbE2trq46LP3WKQ5I-v_NfuhH0X8JTfwl4fQJujYXjfxuL3cW2JEmdn9QmRDjcq6X_IZq2aqn49uFKNJfvv3-mn5h4U_0GvUnBrQ</recordid><startdate>199906</startdate><enddate>199906</enddate><creator>Weir, D. C.</creator><creator>Bale, G. A.</creator><creator>Bright, P.</creator><creator>Sherwood Burge, P.</creator><general>Blackwell Science Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>199906</creationdate><title>A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease</title><author>Weir, D. C. ; Bale, G. A. ; Bright, P. ; Sherwood Burge, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3601-b65e50d9bdfd774cbcffdc5875780d1032465b88efa80cec6fec845b49d73c043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Administration, Inhalation</topic><topic>Aged</topic><topic>Beclomethasone - therapeutic use</topic><topic>Bronchial Provocation Tests</topic><topic>chronic obstructive pulmonary disease</topic><topic>Disease Progression</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>FEV1 decline</topic><topic>Forced Expiratory Volume</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>inhaled beclomethasone</topic><topic>Lung - drug effects</topic><topic>Lung - physiopathology</topic><topic>Lung Diseases, Obstructive - drug therapy</topic><topic>Lung Diseases, Obstructive - physiopathology</topic><topic>Male</topic><topic>Nebulizers and Vaporizers</topic><topic>randomized control trial</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weir, D. C.</creatorcontrib><creatorcontrib>Bale, G. A.</creatorcontrib><creatorcontrib>Bright, P.</creatorcontrib><creatorcontrib>Sherwood Burge, P.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental allergy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weir, D. C.</au><au>Bale, G. A.</au><au>Bright, P.</au><au>Sherwood Burge, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease</atitle><jtitle>Clinical and experimental allergy</jtitle><addtitle>Clinical &amp; Experimental Allergy</addtitle><date>1999-06</date><risdate>1999</risdate><volume>29</volume><issue>s2</issue><spage>125</spage><epage>128</epage><pages>125-128</pages><issn>0954-7894</issn><eissn>1365-2222</eissn><abstract>Treatment of chronic obstructive pulmonary disease (COPD) with inhaled and oral corticosteroids is common, although their exact role is unclear. Previous studies suggest these drugs may reduce decline in lung function in this group of patients. We report a study investigating the effect of inhaled beclomethasone diproprionate (BDP) on lung function and symptoms in a group of patients with COPD. Treatment was given for 2 years, and the decline in FEV1 in individual patients calculated over this period. Ninety‐eight patients were randomized for the study, 59 completing 2 years of treatment. Patients withdrawn had more severe airflow obstruction. Decline in FEV1, measured both prior to and after bronchodilator, was less in patients receiving inhaled BDP, although the differences failed to reach statistical significance except in a subgroup of patients with more severe airflow obstruction. Exacerbation rates were also reduced by inhaled BDP, but again the differences failed to reach conventional levels of statistical significance. The results of this study are consistent with previous published work, but further insight into the long‐term role of corticosteroids in COPD await the publication of large studies which have recently been completed. Although the changes seen in this study and others are numerically small, the rate of decline in FEV1 returned to normal levels expected from age‐related decline, and hence such treatment combined with other strategies may well have a significant role in the long‐term treatment of this condition.</abstract><cop>Oxford BSL</cop><pub>Blackwell Science Ltd</pub><pmid>10421835</pmid><doi>10.1046/j.1365-2222.1999.00021.x</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0954-7894
ispartof Clinical and experimental allergy, 1999-06, Vol.29 (s2), p.125-128
issn 0954-7894
1365-2222
language eng
recordid cdi_proquest_miscellaneous_69917795
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Administration, Inhalation
Aged
Beclomethasone - therapeutic use
Bronchial Provocation Tests
chronic obstructive pulmonary disease
Disease Progression
Double-Blind Method
Female
FEV1 decline
Forced Expiratory Volume
Glucocorticoids - therapeutic use
Humans
inhaled beclomethasone
Lung - drug effects
Lung - physiopathology
Lung Diseases, Obstructive - drug therapy
Lung Diseases, Obstructive - physiopathology
Male
Nebulizers and Vaporizers
randomized control trial
Treatment Outcome
title A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T15%3A02%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20double-blind%20placebo-controlled%20study%20of%20the%20effect%20of%20inhaled%20beclomethasone%20dipropionate%20for%202%20years%20in%20patients%20with%20nonasthmatic%20chronic%20obstructive%20pulmonary%20disease&rft.jtitle=Clinical%20and%20experimental%20allergy&rft.au=Weir,%20D.%20C.&rft.date=1999-06&rft.volume=29&rft.issue=s2&rft.spage=125&rft.epage=128&rft.pages=125-128&rft.issn=0954-7894&rft.eissn=1365-2222&rft_id=info:doi/10.1046/j.1365-2222.1999.00021.x&rft_dat=%3Cproquest_cross%3E43348791%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=199874348&rft_id=info:pmid/10421835&rfr_iscdi=true